TVGN-960 / Tevogen - LARVOL DELTA

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow (GlobeNewswire) - "Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment...'With compelling evidence that SARS-CoV-2 remains a serious threat to those undergoing immunosuppressive treatments and chemotherapy, our first pivotal study with TVGN 489 is being designed specifically to help these vulnerable patients combat the infection.'....Pipeline: TVGN 920: Cervical cancer prevention; TVGN 930: EBV-associated lymphomas; TVGN 960: Mouth and throat cancer; TVGN 601: Multiple sclerosis."

Commercial • Cervical Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Immunology • Lymphoma • Multiple Sclerosis • Novel Coronavirus Disease • Oncology • Oral Cancer • Solid Tumor